HB1265 (2020) Detail

Relative to the requirement of qualifying medical condition for prescriptions for therapeutic cannabis.


HB 1265 - AS INTRODUCED

 

 

2020 SESSION

20-2643

01/04

 

HOUSE BILL 1265

 

AN ACT relative to the requirement of qualifying medical condition for prescriptions for therapeutic cannabis.

 

SPONSORS: Rep. Adjutant, Graf. 17; Rep. Kenney, Straf. 6; Rep. St. Clair, Belk. 9

 

COMMITTEE: Health, Human Services and Elderly Affairs

 

-----------------------------------------------------------------

 

ANALYSIS

 

This bill changes the definition of "qualifying medical condition" in the statute governing the use of cannabis for therapeutic purposes.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

20-2643

01/04

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Twenty

 

AN ACT relative to the requirement of qualifying medical condition for prescriptions for therapeutic cannabis.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  Use of Cannabis for Therapeutic Purposes; Definitions.  RSA 126-X:1, IX is repealed and reenacted to read as follows:

IX.(a)  "Qualifying medical condition" means a medical condition diagnosed by a provider for which cannabis is prescribed for such condition which may include the presence of:

(1)  Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, Ehlers-Danlos syndrome, or one or more injuries or conditions that has resulted in one or more qualifying symptoms under subparagraph (2); and

(2)  A severely debilitating or terminal medical condition or its treatment that has produced at least one of the following: elevated intraocular pressure, cachexia, chemotherapy-induced anorexia, wasting syndrome, agitation of Alzheimer's disease, severe pain that has not responded to previously prescribed medication or surgical measures or for which other treatment options produced serious side effects, constant or severe nausea, moderate to severe vomiting, seizures, or severe, persistent muscle spasms; or

(b)  "Qualifying medical condition" may mean:

(1)  Moderate to severe chronic pain.

(2)  Severe pain that has not responded to previously prescribed medication or surgical measures or for which other treatment options produced serious side effects.

(3)  Moderate or severe post-traumatic stress disorder.

2  Effective Date.  This act shall take effect 60 days after its passage.

Links

HB1265 at GenCourtMobile
HB1265 Discussion

Action Dates

Date Body Type
Jan. 29, 2020 House Hearing
Feb. 13, 2020 House Exec Session
Feb. 18, 2020 House Exec Session

Bill Text Revisions

HB1265 Revision: 6895 Date: Dec. 2, 2019, 1:33 p.m.

Docket

Date Status
Jan. 8, 2020 Introduced 01/08/2020 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 15
Jan. 29, 2020 Public Hearing: 01/29/2020 01:00 pm LOB 205
Feb. 12, 2020 Subcommittee Work Session: 02/12/2020 10:00 am LOB 104
Feb. 13, 2020 Executive Session: 02/13/2020 11:00 am LOB 205
Feb. 18, 2020 ==CONTINUED== Executive Session: 02/18/2020 01:00 pm LOB 205 (if not exec'd on the 13th)
Committee Report: Refer for Interim Study (Vote 17-0; CC)
March 11, 2020 Committee Report: Refer for Interim Study for 03/11/2020 (Vote 17-0; CC) HC 10 P. 18
March 11, 2020 Refer for Interim Study: MA VV 03/11/2020